These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34766242)

  • 1. Towards compatibility of EUnetHTA JCA methodology and German HTA: a systematic comparison and recommendations from an industry perspective.
    Kisser A; Knieriemen J; Fasan A; Eberle K; Hogger S; Werner S; Taube T; Rasch A
    Eur J Health Econ; 2022 Jul; 23(5):863-878. PubMed ID: 34766242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methods for the comparative evaluation of pharmaceuticals.
    Zentner A; Velasco-Garrido M; Busse R
    GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shaping a suitable EU HTA dossier template: why the German template is not fit for purpose.
    Schweitzer MK; Dold MN; Genet A; Gossens K; Klein-Hessling T; Löffler N; Rabel M; Rasch A; Reuter EM; Schmelcher J; Wolfram N; Werner S
    Eur J Health Econ; 2024 Jul; 25(5):877-888. PubMed ID: 37843703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): A first step towards a consolidated European perspective on comparative effectiveness & safety?
    Chassagnol F; Marcelli G; Wagle J; Giuliani G; Traub D; Schaub V; Ruof J
    Health Policy; 2020 Sep; 124(9):943-951. PubMed ID: 32622542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [HTA goes Europe: European collaboration on joint assessment and methodological issues becomes reality].
    Nachtnebel A; Mayer J; Erdös J; Lampe K; Kleijnen S; Schnell-Inderst P; Wild C
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):291-9. PubMed ID: 26354129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EU HTA Regulation and Joint Clinical Assessment-Threat or Opportunity?
    Schuster V
    J Mark Access Health Policy; 2024 Jun; 12(2):100-104. PubMed ID: 38808311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Methodological guideline for the efficacy and safety assessment of new pharmaceuticals: implementation of EUnetHTA's recommendations].
    Ubago Pérez R; Castillo Muñoz MA; Banqueri MG; García Estepa R; Alfaro Lara ER; Vega Coca MD; Beltrán Calvo C; Molina López T
    Gac Sanit; 2017; 31(4):336-341. PubMed ID: 28062129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
    Brettschneider C; Lühmann D; Raspe H
    GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
    Büssgen M; Stargardt T
    Appl Health Econ Health Policy; 2023 Sep; 21(5):751-759. PubMed ID: 37249741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines.
    Grigore B; Ciani O; Dams F; Federici C; de Groot S; Möllenkamp M; Rabbe S; Shatrov K; Zemplenyi A; Taylor RS
    Pharmacoeconomics; 2020 Oct; 38(10):1055-1070. PubMed ID: 32572825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leveraging EUnetHTA's conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer's point of view.
    Giuliani G; Chassagnol F; Traub D; Gyldmark M; Hebborn A; Ducournau P; Ruof J
    Health Econ Rev; 2018 Sep; 8(1):24. PubMed ID: 30242522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European network for Health Technology Assessment Joint Action (EUnetHTA JA): a process evaluation performed by questionnaires and documentary analysis.
    Woodford Guegan E; Cook A
    Health Technol Assess; 2014 Jun; 18(37):1-296. PubMed ID: 24913263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IS THE EUNETHTA HTA CORE MODEL® FIT FOR PURPOSE? EVALUATION FROM AN INDUSTRY PERSPECTIVE.
    Gyldmark M; Lampe K; Ruof J; Pöhlmann J; Hebborn A; Kristensen FB
    Int J Technol Assess Health Care; 2018 Jan; 34(5):458-463. PubMed ID: 30334508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases.
    Staab T; Isbary G; Amelung VE; Ruof J
    BMC Health Serv Res; 2016 Nov; 16(1):651. PubMed ID: 27842592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Market withdrawals" of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations.
    Staab TR; Walter M; Mariotti Nesurini S; Dintsios CM; Graf von der Schulenburg JM; Amelung VE; Ruof J
    Health Econ Rev; 2018 Sep; 8(1):23. PubMed ID: 30229501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is IQWiG's 15% Threshold Universally Applicable in Assessing the Clinical Relevance of Patient-Reported Outcomes Changes? An ISPOR Special Interest Group Report.
    Schlichting M; Hennig M; Rudell K; McLeod L; Bennett B; Shaw J; Doward L; Molsen-David E; Chassany O
    Value Health; 2022 Sep; 25(9):1463-1468. PubMed ID: 36049796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.